![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AM-Pharma |
---|---|
Information provided by: | AM-Pharma |
ClinicalTrials.gov Identifier: | NCT00430469 |
The safety and tolerability of hLF 1-11 given in multiple doses has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complications due to invasive fungal or bacterial disease. These patients are different from healthy volunteers because they have received myeloablative treatment, which not only arrests haematopoiesis resulting in neutropenia but also induces mucosal barrier injury both of which predispose to infections, which typically occur during the week after transplant. It is therefore essential to know that hLF 1-11 is safe and well tolerated when given during neutropenia and mucosal barrier injury before infections ensue.
Condition | Intervention | Phase |
---|---|---|
Fungal Infection Bacterial Infection |
Drug: human lactoferrin (hLF1-11) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients |
Estimated Enrollment: | 8 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Human lactoferrin (hLF) is a glycoprotein containing 692 amino acids and found in the saliva, milk, tears, and other body fluids. The peptide representing the first cationic domain, i.e. the peptide comprising the first eleven residues of hLF (further referred to as hLF1-11) was significantly more effective than the full length protein or the peptide representing the second cationic domain. As with other antimicrobial peptides, hLF1-11 shows poor antimicrobial activity under physiological conditions in vitro, but it is highly effective in vivo against infections due to a variety of microorganisms, including Gram negative and Gram positive bacteria and fungi. The objective is to develop hLF1-11 for the treatment of fungal and bacterial infections that develop during neutropenia that results from myeloablative therapy to prepare for a haematopoietic stem cell transplant(HSCT) formerly referred to as bone marrow transplant. Rates of infection and related morbidity are high in this population, making it an attractive target for testing clinically the proof-of-principle that hLF1-11 can provide effective treatment. Subsequently, hLF1-11 will be developed further as a systemic antifungal agent
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Recipients will be eligible for inclusions if they satisfy the following conditions:
Contact: J. Arend, MD | +31 (0)30 228 92 22 | J.Arend@AM-Pharma.com |
Netherlands, Gelderland | |
UMC St. Radboud | |
Nijmegen, Gelderland, Netherlands, 6500 HB |
Principal Investigator: | Peter J Donnelly, PhD | UMC St. Radboud Nijmegen |
Responsible Party: | AM-Pharma ( Dr J Arend, MD ) |
Study ID Numbers: | AMP 02-02; SC13, EudraCT No. 2006-004012-52 |
Study First Received: | February 1, 2007 |
Last Updated: | October 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00430469 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Lactoferrin hLF Neutropenia Myeloablative Treatment |
Fungal Bacterial Infections Bone marrow transplant |
Bacterial Infections Neutropenia Mycoses |
Communicable Diseases Infection |